Christopher Waddick
Net worth: 165 798 $ as of 2026-05-30
Net worth: 165 798 $ as of 2026-05-30
Christopher J.
Waddick is Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022, President & Chief Financial Officer at Active Energy, Inc. since 2013, and President at Nrj Consulting, Inc. since 2009.
Formerly, Mr. Waddick was Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Education includes an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-12-29 | 135,900 ( 0.12% ) | 165 798 $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Director of Finance/CFO | 2018-08-15 |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Director of Finance/CFO | 2012-12-31 |
Nrj Consulting, Inc. | President | 2009-10-31 |
| Companies | Position | End |
|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wilfrid Laurier University
Wilfrid Laurier University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Utilities |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Nrj Consulting, Inc. |
Select your edition
All financial news and data tailored to specific country editions